Jon L. Collins, PhD
Jon Collins received his BS degree in chemistry from the University of North Carolina at Chapel Hill and a PhD in organic chemistry with a minor in biochemistry at Indiana University at Bloomington. After completion of a postdoctoral fellowship at Harvard University in the labs of Professor Stuart Schreiber, he joined GlaxoSmithKline in 1995 and has since led drug discovery research teams that span novel target selection, hit identification and optimization in multiple target classes, lead optimization to candidate selection, and design of proof of concept clinical studies. Jon has collaborated extensively with the academic community throughout his scientific career and recently joined the Discovery Partnerships with Academia team within GlaxoSmithKline in order to establish and lead joint academic-GSK drug discovery collaborations in the US.
GlaxoSmithKline Research & Development
Our scientists are working hard to discover new ways of treating and preventing diseases. By combining the wide-ranging talents of our R&D employees with our leading edge science resources, we are dedicated to bringing more medicines of value to patients.
Our product pipeline is diverse and changes over time as new molecules progress from discovery to development and ultimately to approval where they become available to patients.
But this process requires time and investment. It takes about 12-15 years and costs over £500 million to discover and develop a new medicine or vaccine, so we need to be determined and innovative to help new molecules progress into medicines. One of our aims is to try to shorten the amount of time it takes to safely develop these medicines and vaccines.
We are one of the largest collaborators in industry and work with academic institutions, governments, and other pharmaceutical and biotechnology companies. We believe that the strength of our combined efforts will ultimately help people do more, feel better and live longer.